Mr. Pierre Montanaro reports

DEVONIAN ANNOUNCES CLOSING OF A PRIVATE PLACEMENT OF $1.2 MILLION

Devonian Health Group Inc. has closed its non-brokered previously announced private placement for aggregate gross proceeds of $1,199,664.75. The offering consisted of the issuance of 7,997,765 units of the corporation at a price of 15 cents per unit. Each unit consists of one subordinate voting share of the corporation and one share purchase warrant. Each warrant entitles the holder thereof to purchase one share at an exercise price of 20 cents per share for a period of 24 months from the date of issuance thereof.

The proceeds of the offering will mainly be used to finance the preparation of clinical study programs for Thykamine in particular the phase 2/3 program in pediatric atopic dermatitis, the phase 2 programs in radiodermatitis associated with radiotherapy, and in hand and foot syndrome and associated with chemotherapy and also for working capital relating to the general and administrative expenses of the corporation.

No finders' fees were paid in connection with this offering. The shares and the warrants issued pursuant to this offering are subject to a restricted hold period of four months and one day, ending on Oct. 7, 2023, under applicable Canadian securities laws. The offering remains subject to the final approval of the TSX Venture Exchange.

Under the offering, insiders of the corporation, more specifically directors and officers of the corporation, collectively subscribed for a total of 800,000 units for a total consideration of $120,000 which constitutes a related party transaction within the meaning of Regulation 61-101 respecting Protection of Minority Security Holders in Special Transactions and TSX-V Policy 5.9 -- Protection of Minority Security Holders in Special Transaction. However, the directors of the corporation who voted in favour of the offering have determined, based on advice from counsel and management, that the exemptions from formal valuation and minority approval requirements provided for respectively under subsections 5.5(a) and 5.7(1)(a) of Regulation 61-101 can be relied on as neither the fair market value of the units issued to insiders nor the fair market value of the consideration paid exceed 25 per cent of the corporation's market capitalization. None of the corporation's directors has expressed any contrary views or disagreements with respect to the foregoing. A material change report in respect of this related party transaction will be filed by the corporation, but could not be filed earlier than 21 days prior to the closing of the offering due to the fact that the terms of the participation of each of the non-related parties and the related parties in the offering were not confirmed.

About Devonian Health Group Inc.

Devonian is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory autoimmune diseases, including, but not limited to, ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with its pharmaceutical offerings. Devonian was incorporated in 2015 and is headquartered in Quebec, Canada, where it owns a state-of-the art extraction facility with full traceability from the seed to the pill. Acquired in 2018, Altius Healthcare Inc., its commercialization subsidiary, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the exchange (TSX Venture Exchange: GSD) and on the OTCQB Exchange (OTCQB: DVHGF).

We seek Safe Harbor.